miR-146a and miR-152 in prostate cancer and clinicopathological parameters.
To investigate the expression of miR-146a and miR-152 in the serum of patients with prostate cancer and the relationship between their expression and clinicopathologic parameters. 56 patients with prostate cancer and 56 healthy volunteers were included in this study and the relationship between the expression levels of miR-146a and miR-152 and the clinicopathological parameters of the patients with prostate cancer were analyzed. ROC curve was used to search the diagnostic value of each indicator. The expression of miR-146a in patients in the cancer group was significantly higher than that in the normal group (p<0.05). The expression of miR-152 in the cancer group was significantly lower than that in the normal group (p<0.05). The expression level of miR-146a in the patients with prostate cancer was closely related to clinical staging, the presence or absence of bone metastasis, tPSA and pathological staging (p<0.001) and the expression level of miR-152 in the patients with prostate cancer was closely related to clinical staging, the presence or absence of bone metastasis and pathological staging (p<0.001). The expression level of miR-146a showed a trend of up-regulation in prostate cancer, and the expression level of miR-152 had a trend of down-regulation in prostate cancer, and the results of partial correlation analysis showed that the expression level of miR-146a and miR-152 was negatively correlated with each other in the serum of the patients with prostate cancer.